WILMINGTON, Del., July 17, 2017 -- Rigrodsky & Long, P.A.:
Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Nebraska on behalf of holders of West Corporation (“West”) (Nasdaq:WSTC) common stock in connection with the proposed acquisition of West by affiliates of Apollo Global Management, LLC (collectively, “Apollo”) announced on May 9, 2017 (the “Complaint”). The Complaint, which alleges violations of the Securities Exchange Act of 1934 against West, its Board of Directors (the “Board”), and Apollo, is captioned Scarantino v. West Corp., Case No. 4:17-cv-03080 (D. Neb.).
If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail at [email protected], or at http://rigrodskylong.com/contact-us/.
On May 9, 2017, West entered into an agreement and plan of merger (the “Merger Agreement”) with Apollo. Pursuant to the Merger Agreement, shareholders of West will receive $23.50 per share in cash (the “Proposed Transaction”).
Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a proxy statement (the “Proxy Statement”) filed with the United States Securities and Exchange Commission on June 15, 2017. The Complaint alleges that the Proxy Statement, which recommends that West stockholders vote in favor of the Proposed Transaction, omits material information necessary to enable shareholders to make an informed decision as to how to vote on the Proposed Transaction, including material information with respect to West’s financial projections, the analyses performed by West’s financial advisor, and the background of the Proposed Transaction. The Complaint seeks injunctive and equitable relief and damages on behalf of holders of West common stock.
If you wish to serve as lead plaintiff, you must move the Court no later than September 15, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Seth D. Rigrodsky Gina M. Serra (888) 969-4242 (302) 295-5310 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com


Apple Turns 50: From Garage Startup to AI Crossroads
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 



